QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

22,972 signal articles · 266 in last 24h · 110,068 total before filter · latest 56m ago
266last 24h
2418last 7d
434● bullish (7d)
227● bearish (7d)
202publishers
AllMacro252Earnings1479M&A101Regulatory16Product17Analyst23
✕ clear all filtersSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Boston Scientific (NYSE:BSX) Surprises With Q2 CY2026 Sales But Quarterly Revenue Guidance Misses Expectations
StockStory13d agobearish
Boston Scientific (NYSE:BSX) Surprises With Q2 CY2026 Sales But Quarterly Revenue Guidance Misses Expectations

Medical device company Boston Scientific (NYSE:BSX) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 7.5% year on year to $5.44 billion. On the other hand, next quarter’s revenue guidance of $5.27 billion was less impressive, coming in 2.2% below analysts’ estimates. Its non-GAAP profit of $0.86 per share was 3.8% above analysts’ consensus estimates.

United Microelectronics Q2 Earnings Call Highlights
MarketBeat13d agoneutral
United Microelectronics Q2 Earnings Call Highlights

United Microelectronics (NYSE:UMC) reported higher second-quarter revenue, wafer shipments and utilization as demand strengthened in communications and consumer applications, while the company raised its 2026 capital-expenditure budget to support silicon photonics and advanced-packaging growth initi

Ford Shares Rise After Q2 Earnings Beat and Higher Full-Year Guidance
InvestorsHub13d agobullish
Ford Shares Rise After Q2 Earnings Beat and Higher Full-Year Guidance

Ford Motor Company (NYSE:F) shares climbed more than 4% after the automaker reported better-than-expected second-quarter results and raised its financial outlook for the full year, supported by stronger operating performance across its core business. The company posted adjusted earnings per share of $0.

Investing.com13d agobullish
Vertiv shares sink as Q2 revenue miss offsets upgraded guidance

Investing.com -- Shares in Vertiv tumbled more than 9% in premarket trading Wednesday even as the data center equipment maker reported second-quarter earnings above estimates and raised its full-year guidance, with a revenue shortfall offseting the beat.

KLA Shares Drop Despite Q4 Earnings Beat as Guidance Fails to Impress Investors
InvestorsHub13d agoneutral
KLA Shares Drop Despite Q4 Earnings Beat as Guidance Fails to Impress Investors

KLA Corporation (NASDAQ:KLAC) reported stronger-than-expected fiscal fourth-quarter results, but its shares fell more than 10% in pre-market trading on Wednesday after investors focused on a cautious near-term outlook and guidance that offered only limited upside. The semiconductor equipment manufacturer posted earnings per share of $1.

Higher Earnings Forecasts and Opdivo Combo Filing Might Change The Case For Investing In Bristol-Myers Squibb (BMY)
Simply Wall St.13d agoneutral
Higher Earnings Forecasts and Opdivo Combo Filing Might Change The Case For Investing In Bristol-Myers Squibb (BMY)

In recent days, Bristol Myers Squibb has been in focus as analysts updated earnings forecasts and a biotech partner sought approval for its first commercial product to be used alongside BMS’s cancer drug Opdivo. At the same time, commentators have highlighted Bristol Myers Squibb’s role as a dividend-oriented value name with a pipeline viewed as important for offsetting future patent expirations and evolving product sales trends. Building on this, we’ll explore how higher earnings...